Promising Safety, Tolerability and Efficacy Results from Morria Biopharmaceuticals Plc' MRX-4 Phase II Study in Allergic Rhinitis to be Presented at the upcoming EAACI Congress

Published: Jun 03, 2010

LONDON & NEW YORK--(BUSINESS WIRE)--Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today that it will be presenting the results from its ICH compliant Phase II study of MRX-4 (n=105) in patients suffering from allergic rhinitis at the upcoming 29th EAACI Congress (European Academy of Allergy and Clinical Immunology) in London on June 7th. The results will be presented by the study‘s principal investigator Prof. Eric Bateman.

Back to news